Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Qatar Investment Authority
BioCentury | Aug 1, 2024
Finance
Venture Report: venBio closes new $528M fifth fund
Plus: Airna, ReviR, LTZ and Synthetica draw Series A cash, while Outpace, Confo and Healx refill their coffers
BioCentury | Jun 14, 2024
Finance
Venture Report: Clinical plays Alzheon, Bright Peak raise growth capital
Plus: Early-stage financings for InduPro, Syntis and Moleculent; J.P. Morgan closes its life sciences vehicle; and a new fund for spinal injury
BioCentury | Jun 14, 2024
Management Tracks
Connect leans into its U.S. profile as it remakes its leadership
Plus: Medivation vet Hung now chair of T-Therapeutics and updates from Voyager and Eyenuk
BioCentury | Oct 6, 2023
Regulation
Oct. 5 Quick Takes: FDA panel declines to back Lumakras
Plus: Mirati rises after Sanofi takeout rumor circulates, ODAC panel and updates from Kyowa Kirin, AbbVie, Evotec, FDA, Precede and more
BioCentury | Sep 25, 2023
Product Development
Sept. 25 Quick Takes: Novartis’ Lutathera meets primary for first-line GEP-NETs
Plus: Japan’s latest drug approvals and updates from Junshi, Adela, AbbVie, I-Mab, Novo, Valo, BridgeBio, GSK, Scynexis
BioCentury | Sep 5, 2023
Deals
Sept. 5 Quick Takes: Moulder’s Zenas in regional deal with BMS for bispecific
Plus: Beam moves base editors into the clinic and updates on Star, Tivdak, Olema and Insmed’s Arikayce
BioCentury | Jun 7, 2023
Finance
June 7 Quick Takes: Radiopharma play ITM raises €255M
Plus: LNP company Hopewell emerges with $25M seed round and updates from Mozart, GSK, FibroGen and Deerfield
BioCentury | Mar 1, 2023
Finance
China venture roundup: RNA company Immorna raises nearly $100M
Plus: Fresh funding for Eluminex and Oricell
BioCentury | Jan 6, 2023
Deals
In vivo cell therapy technology advances with Ensoma’s Twelve Bio acquisition
Ensoma raises $85M in series B led by Arix, 5AM and acquires gene editing company Twelve Bio
BioCentury | Aug 17, 2022
Regulation
Aug. 16 Quick Takes: Everest extends runway by offloading Trodelvy
Plus Flagship’s Senda raises $123M and updates from Bluejay, AZ, Ventyx and more
Items per page:
1 - 10 of 28